US-based biotechnology firm Audentes Therapeutics has commenced patient dosing in the Phase I/II ASPIRO clinical trial of its product candidate AT132 to treat X-linked myotubular myopathy (XLMTM). 

AT132 contains an AAV8 vector with a functional copy of the MTM1 gene, while XLMTM is a rare monogenic disease caused by MTM1 gene mutations leading to muscle weakness, respiratory failure and early death.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The multi-centre, multi-national, open-label, ascending dose Phase I/II trial will investigate the safety and preliminary efficacy of AT132 in around 12 patients aged less than five years. 

ASPIRO is designed to include nine subjects treated with AT132 and three delayed treatment concurrent control subjects.

Audentes Therapeutics senior vice-president and chief medical officer Suyash Prasad said: "Over 50% of the boys affected by XLMTM do not live to celebrate their second birthday, and no currently approved treatment options exist for these patients, their families and caregivers.

"We look forward to working together with our partners to advance AT132 as a potentially transformative therapy to treat this devastating disease."

“We look forward to working together with our partners to advance AT132 as a potentially transformative therapy to treat this devastating disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary endpoints are safety and efficacy, while the secondary endpoints include disease burden, health related quality of life, muscle tissue histology and biomarkers.

A primary efficacy assessment is scheduled to be conducted at 12 months, after which patients are expected to undergo a follow-up for additional four years for the evaluation of long-term safety, effect durability and developmental progression.

It is estimated that preliminary results from the trial will be reported in the fourth quarter of this year.